Atumelnant

Crinetics Pharmaceuticals is testing atumelnant, a first-in-class oral ACTH receptor (MC2R) antagonist, in a Phase 3 trial for classic congenital adrenal hyperplasia (CAH) - a genetic disorder where faulty cortisol production triggers dangerous androgen overload [1]. Phase 2 data showed up to 80% reduction in the key androgen marker androstenedione, with no serious adverse events across 750+ patient-weeks of exposure [2]. The competitive reality is stark: Neurocrine's crinecerfont (CRENESSITY), which works through a different mechanism, won FDA approval in December 2024 and pulled in $301M in its first year on market [3].

Atumelnant is a novel compound, never approved for any indication. The Phase 3 CALM-CAH trial (NCT07144163) dosed its first patient in December 2025, enrolling 150 adults with classic CAH [1]. A parallel Phase 2/3 pediatric study (BALANCE-CAH, NCT07159841, n=153) started in January 2026 [4]. The FDA granted Orphan Drug Designation in August 2025, which provides seven years of market exclusivity upon approval and waived regulatory fees [5]. No breakthrough therapy or fast track designations have been announced. Crinetics has not disclosed expected readout timing, but given the trial just started recruiting and needs to enroll 150 patients in a rare disease population, topline data likely arrives no earlier than 2028. The company is also running an early-stage Phase 1/2b trial of atumelnant in ACTH-dependent Cushing's syndrome, broadening the drug's potential addressable market beyond CAH [5]. With $1.4 billion in cash following a January 2026 public offering, Crinetics has the financial runway to execute the full development program without needing to raise more capital near-term [5].

In classic CAH, patients are born without functional 21-hydroxylase - an enzyme the adrenal glands need to manufacture cortisol. Without cortisol, the pituitary gland keeps firing ACTH (adrenocorticotropic hormone), the chemical signal that tells the adrenals to produce more. The adrenals cannot make cortisol no matter how hard they're pushed, but all that ACTH stimulation drives them to overproduce androgens through alternative biochemical pathways [6]. For 70 years, the only treatment was supraphysiologic glucocorticoids - flooding patients with synthetic cortisol to suppress ACTH at the pituitary. The catch: chronic high-dose steroids cause obesity, diabetes, bone loss, cardiovascular disease, and growth suppression in children. CAH patients have 2-5x higher mortality than the general population, partly from the disease and partly from its treatment [6]. Atumelnant takes a fundamentally different approach from the CRF1 receptor antagonists (crinecerfont, the now-failed tildacerfont). Those drugs work upstream, blocking the brain's signal to release ACTH. Atumelnant works downstream - it blocks the ACTH receptor (MC2R) directly on adrenal cells [2]. Even when ACTH is elevated, the adrenals cannot respond, so androgen production drops. This lets patients step down to normal-dose glucocorticoids, replacing what the body should make without the excess needed to suppress ACTH. The MC2R target is genetically validated: ACTH is the direct driver of adrenal androgen excess in CAH, and blocking its receptor addresses the root cause at the gland itself.

CALM-CAH (NCT07144163) is a randomized, double-blind, placebo-controlled Phase 3 trial in 150 adults with classic CAH due to 21-hydroxylase deficiency [1]. The dose is 80 mg once daily, selected from the Phase 2 dose-ranging study where 80 mg showed the best balance of efficacy and tolerability [2]. The primary endpoint is a composite: the proportion of patients who achieve normalized morning androstenedione (A4 at or below the upper limit of normal) while simultaneously on physiologic glucocorticoid replacement (below 11 mg/m²/day hydrocortisone equivalents). This is a deliberately tough bar - it requires the drug to control androgens and enable steroid dose reduction at the same time, not just one or the other. First patient was dosed in December 2025 [5]. The pediatric program BALANCE-CAH (NCT07159841, n=153) runs in parallel with a three-part design: Phase 2 dose-ranging followed by a Phase 3 double-blind, placebo-controlled confirmatory study in children and adolescents [4]. CRN04894 previously carried the internal designation; atumelnant received its INN (international nonproprietary name) as the compound matured. The completed Phase 1 PK bridging study in Japanese and Caucasian healthy volunteers (NCT07221084, n=21) supports global development [7]. An open-label extension study (NCT06712823, n=150) is also enrolling to capture long-term safety data from Phase 2 participants [8].

Our model puts this drug's chance of eventual approval at 31%. That number starts from the historical approval rate for Phase 3 drugs in this area - about 66% - and is then adjusted using ten specific facts about the trial and its sponsor. Strong earlier-phase results push the estimate up, while the sponsor's weak approval track record, heavier-than-usual blinding, and a randomized trial design pull it down. The remaining factors were close to average and left the estimate roughly where the base rate set it.

Atumelnant is a genuine watch-list asset, not noise. The MC2R mechanism is scientifically differentiated from CRF1 antagonism - blocking ACTH at the gland rather than at the brain is a cleaner approach in theory, and the Phase 2 composite data backs this up. The question is whether that scientific differentiation translates to a clinical difference large enough to overcome crinecerfont's market entrenchment [6]. The data point that would change the calculus: if Phase 3 CALM-CAH shows a meaningfully higher proportion of patients achieving the composite endpoint (normalized androgens on physiologic glucocorticoids) than crinecerfont achieved in its Phase 3 trials, that creates a best-in-class argument that could sway endocrinologists. CRENESSITY's pricing at ~$460K/year means even modest CAH market share is financially significant - a 20-30% share translates to $60-100M in annual revenue for Crinetics [3]. For Crinetics as a company, the near-term catalyst is PALSONIFY (paltusotine), its oral acromegaly drug approved in September 2025, which is still in early launch ($5.4M in Q4 2025 revenue) [5]. Atumelnant is the medium-term pipeline story. With $1.4B in cash, the company does not need to make compromises on trial design or development speed for financial reasons. Check back when Phase 3 enrollment completes or at interim analysis, likely mid-to-late 2027.